使用可穿戴心电图 (ECG) 传感器区分可卡因使用与其他拟交感神经药物。

Discriminating cocaine use from other sympathomimetics using wearable electrocardiographic (ECG) sensors.

机构信息

Department of Psychiatry, Yale University School of Medicine, New Haven, CT06519, USA; Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park Street, New Haven, CT06519, USA; Connecticut Mental Health Center, New Haven, CT06519, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

Department of Psychiatry, Yale University School of Medicine, New Haven, CT06519, USA; Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT06510, USA.

出版信息

Drug Alcohol Depend. 2023 Sep 1;250:110898. doi: 10.1016/j.drugalcdep.2023.110898. Epub 2023 Jul 14.

DOI:10.1016/j.drugalcdep.2023.110898

PMID:37523916

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10905422/

Abstract

BACKGROUND

Our group has established the feasibility of using on-body electrocardiographic (ECG) sensors to detect cocaine use in the human laboratory. The purpose of the current study was to test whether ECG sensors and features are capable of discriminating cocaine use from other non-cocaine sympathomimetics.

METHODS

Eleven subjects with cocaine use disorder wore the Zephyr BioHarness™ 3 chest band under six experimental (drug and non-drug) conditions, including 1) laboratory, intravenous cocaine self-administration, 2) after a single oral dose of methylphenidate, 3) during aerobic exercise, 4) during tobacco use (N=7 who smoked tobacco), and 5) during routine activities of daily inpatient living (unit activity). Three ECG-derived feature sets served as primary outcome measures, including 1) the RR interval (i.e., heart rate), 2) a group of ECG interval proxies (i.e., PR, QS, QT and QTc intervals), and 3) the full ECG waveform. Discriminatory power between cocaine and non-cocaine conditions for each of the three outcomes measures was expressed as the area under the receiver operating characteristics (AUROC) curve.

RESULTS

All three outcomes successfully discriminated cocaine use from unit activity, exercise, tobacco, and methylphenidate conditions with a mean AUROC values ranging from 0.66 to 0.99 and with least squares means values all statistically different/higher than 0.5 among all subjects [F(3, 99) = 3.38, p =0.02] and among those with tobacco use [F(4, 84) = 5.39, p = 0.0007].

CONCLUSIONS

These preliminary results support discriminatory power of wearable ECG sensors for detecting cocaine use.

摘要

背景

我们的团队已经证实，使用体戴式心电图（ECG）传感器在人体实验室检测可卡因使用是可行的。本研究的目的是测试 ECG 传感器和特征是否能够区分可卡因的使用与其他非可卡因拟交感神经药物的使用。

方法

11 名可卡因使用障碍患者在 6 种实验（药物和非药物）条件下佩戴 Zephyr BioHarness™ 3 胸部带，包括 1）实验室，静脉内可卡因自我给药，2）单次口服哌甲酯后，3）有氧运动期间，4）吸烟（7 人吸烟）期间，以及 5）住院日常活动期间（单位活动）。三个 ECG 衍生特征集作为主要结果测量指标，包括 1）RR 间隔（即心率），2）一组 ECG 间隔代理（即 PR、QS、QT 和 QTc 间隔），以及 3）完整的 ECG 波形。三种结果测量指标中可卡因与非可卡因条件之间的区分能力用接受者操作特征（ROC）曲线下面积（AUROC）表示。

结果

所有三种结果均成功区分了可卡因使用与单位活动、运动、吸烟和哌甲酯条件，平均 AUROC 值范围为 0.66 至 0.99，所有受试者的最小二乘均值均高于 0.5 [F(3, 99) = 3.38, p = 0.02]，且吸烟者的最小二乘均值均高于 0.5 [F(4, 84) = 5.39, p = 0.0007]。